Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20181113041635N1
IRCT20181113041635N1
Completed
Phase 3

The effect of Combination Peg interferon –alpha to Tenofovir versus each one of the treatment modalities alone on Patients with HBeAg-negative: A randomized clinical trial

vice presidency for siences and technology , Iran national silences foundation0 sites60 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
vice presidency for siences and technology , Iran national silences foundation
Enrollment
60
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
vice presidency for siences and technology , Iran national silences foundation

Eligibility Criteria

Inclusion Criteria

  • •Patients with the age of 18\-65 years
  • •Negative Hepatitis B e antigen at baseline
  • •Quantifiable serum hepatitis B viral DNA load\> 2000 IU/ml
  • •At least six months from the initial diagnosis
  • •Those with no history of receiving an antiviral drug

Exclusion Criteria

  • •Hepatitis C, D and HIV Viruses co\-infection
  • •Dialysis patients with renal impairment
  • •Severe liver diseases
  • •History of previous hepatitis B treatment (for at least 30 days)
  • •Other liver comorbidities such as Autoimmune Hepatitis Hepatocellular Carcinoma, uncompensated cirrhosis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Phase 3
A study of peginterferon alfa-2a in combination with ribavirin in patients with chronic Hepatitis C.Chronic hepatitis C
JPRN-jRCT2080220023Chugai Pharmaceutical Co., Ltd.
Unknown
Phase 2
A study of peginterferon alfa-2a in combination with ribavirin in chronic hepatitis C(CHC) patients with compensated liver cirrhosis(LC).CHC with compensated LC
JPRN-jRCT2080220215Chugai Pharmaceutical Co., Ltd.
Completed
Not Applicable
The effectiveness of peginterferon -alpha2a and the entecavir combination therapy for the chronic hepatitis B patient
JPRN-UMIN000016275Kinki University School of Medicine50
Completed
Phase 3
Effect of Pegylated Interferon alfa-2a plus Adefovir in the treatment of chronic hepatitis B with genotype DChronic hepatitis B.Chronic viral hepatitis B without delta-agent
IRCT138711201155N4Guilan University of Medical Sciences74
Active, not recruiting
Not Applicable
Trial to compare the responses in two strata of patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia. Each patient will receive PEGASYS (Pegylated Interferon Alfa-2a) or Hydroxyurea (also known as Hydroxycarbamide). The treatment assigned will be chosen by chance.High Risk Polycythemia Vera or High Risk Essential ThrombocythemiaMedDRA version: 14.1Level: PTClassification code 10036057Term: Polycythaemia veraSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2010-019501-41-SECONSORZIO MARIO NEGRI SUD612